Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (351-360 of 635) with videos related to

Pageof 64
Sort By:
The American Journal of Medicine|January 28, 2010
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromesRenato D Lopes, Aijing Starr, Carl F Pieper, et al.
The American Journal of Cardiology|March 9, 2019
Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry)Sreekanth Vemulapalli, Taku Inohara, Sunghee Kim, et al.
JAMA Network Open|January 16, 2019
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID TrialJ Antonio Gutierrez, Hillary Mulder, W Schuyler Jones, et al.
American Heart Journal|November 6, 2018
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart StudyMintu P Turakhia, Manisha Desai, Haley Hedlin, et al.
Circulation|September 10, 2008
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialChristopher E Buller, Yuling Fu, Kenneth W Mahaffey, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The impact of postrandomization crossover of therapy in acute coronary syndromes careKenneth W Mahaffey, Karen S Pieper, Yuliya Lokhnygina, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
American Heart Journal|February 9, 2018
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialPatrícia O Guimarães, Sergio Leonardi, Zhen Huang, et al.
Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 64

Showing results (351-360 of 635) with videos related to

Sort By:
Pageof 64
The American Journal of Medicine|January 28, 2010
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromesRenato D Lopes, Aijing Starr, Carl F Pieper, et al.
The American Journal of Cardiology|March 9, 2019
Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry)Sreekanth Vemulapalli, Taku Inohara, Sunghee Kim, et al.
JAMA Network Open|January 16, 2019
Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID TrialJ Antonio Gutierrez, Hillary Mulder, W Schuyler Jones, et al.
American Heart Journal|November 6, 2018
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart StudyMintu P Turakhia, Manisha Desai, Haley Hedlin, et al.
Circulation|September 10, 2008
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialChristopher E Buller, Yuling Fu, Kenneth W Mahaffey, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The impact of postrandomization crossover of therapy in acute coronary syndromes careKenneth W Mahaffey, Karen S Pieper, Yuliya Lokhnygina, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
American Heart Journal|February 9, 2018
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialPatrícia O Guimarães, Sergio Leonardi, Zhen Huang, et al.
Heart Rhythm O2|August 2, 2021
Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AFFrancis E Ugowe, Anne S Hellkamp, Allen Wang, et al.
American Heart Journal|June 15, 2018
Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Pageof 64